Immunohistochemistry analysis of Phospho-c-Met [pY1003] showing staining in the cytoplasm and membrane of paraffin-embedded mouse liver tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a Phospho-c-Met [pY1003] polyclonal antibody (44882G) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Dog, Hamster, Mouse, Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human c-Met that contains tyrosine 1003. The sequence is conserved in mouse and rat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20-1:200|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The c-Met oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a trans-membrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. The c-Met gene product has been identified as the cell surface receptor for hepatocyte growth factor, a plasminogen-like protein thought to be a humoral mediator of liver regeneration.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
44-882G was used in immunohistochemistry to investigate the role of mTOR and Wnt signaling proteins to c-Met TKI resistance in melanoma cell lines
|Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N||Cancer biology and therapy (15:1129)||2014|
Expression of hepatocyte epidermal growth factor receptor, FAS and glypican 3 in EpCAM-positive regenerative clusters of hepatocytes, cholangiocytes, and progenitor cells in human liver failure.
44-882G was used in immunohistochemistry to study regenerative clusters in the liver histologically.
|Hattoum A,Rubin E,Orr A,Michalopoulos GK||Human pathology (44:743)||2013|
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
44-882G was used in western blot to study the molecular mechanisms underlying development of resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
|Fong JT,Jacobs RJ,Moravec DN,Uppada SB,Botting GM,Nlend M,Puri N||PloS one (8:null)||2013|
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
44-882G was used in western blot to examine the anticancer effect of a novel anti-c-MET Nanobody in multiple myeloma.
|Slørdahl TS,Denayer T,Moen SH,Standal T,Børset M,Ververken C,Rø TB||European journal of haematology (91:399)||2013|
|Not Applicable||Not Cited||
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
44-882G was used in western blot to study MET receptor tyrosine kinase as a potential novel therapeutic target for head and neck squamous cell carcinoma
|Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R||Cancer research (69:3021)||2009|
|Human||Not Cited||Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.||Ma PC,Jagadeeswaran R,Jagadeesh S,Tretiakova MS,Nallasura V,Fox EA,Hansen M,Schaefer E,Naoki K,Lader A,Richards W,Sugarbaker D,Husain AN,Christensen JG,Salgia R||Cancer research (65:1479)||2005|
|A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.||Christensen JG,Schreck R,Burrows J,Kuruganti P,Chan E,Le P,Chen J,Wang X,Ruslim L,Blake R,Lipson KE,Ramphal J,Do S,Cui JJ,Cherrington JM,Mendel DB||Cancer research (63:7345)||2003|
MET and phosphorylated MET as potential biomarkers in lung cancer.
44-882G was used in immunohistochemistry to assess expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor in patients with lung cancer.
|Tretiakova M,Salama AK,Karrison T,Ferguson MK,Husain AN,Vokes EE,Salgia R||Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer (30:341)||2011|